Next Article in Journal
Macrophages Cytokine Spp1 Increases Growth of Prostate Intraepithelial Neoplasia to Promote Prostate Tumor Progression
Previous Article in Journal
Roles of Nitric Oxide in Brain Ischemia and Reperfusion
Previous Article in Special Issue
A Rheostat of Ceramide and Sphingosine-1-Phosphate as a Determinant of Oxidative Stress-Mediated Kidney Injury
Review

Implications of Sphingolipid Metabolites in Kidney Diseases

1
Katz Family Division of Nephrology and Hypertension, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
2
Peggy and Harold Katz Family Drug Discovery Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Norishi Ueda
Int. J. Mol. Sci. 2022, 23(8), 4244; https://doi.org/10.3390/ijms23084244
Received: 4 February 2022 / Revised: 8 April 2022 / Accepted: 10 April 2022 / Published: 11 April 2022
(This article belongs to the Special Issue The Role of Sphingolipids in Oxidative Stress)
Sphingolipids, which act as a bioactive signaling molecules, are involved in several cellular processes such as cell survival, proliferation, migration and apoptosis. An imbalance in the levels of sphingolipids can be lethal to cells. Abnormalities in the levels of sphingolipids are associated with several human diseases including kidney diseases. Several studies demonstrate that sphingolipids play an important role in maintaining proper renal function. Sphingolipids can alter the glomerular filtration barrier by affecting the functioning of podocytes, which are key cellular components of the glomerular filtration barrier. This review summarizes the studies in our understanding of the regulation of sphingolipid signaling in kidney diseases, especially in glomerular and tubulointerstitial diseases, and the potential to target sphingolipid pathways in developing therapeutics for the treatment of renal diseases. View Full-Text
Keywords: sphingolipids; glomerular diseases; tubulointerstitial diseases sphingolipids; glomerular diseases; tubulointerstitial diseases
Show Figures

Figure 1

MDPI and ACS Style

Mallela, S.k.; Merscher, S.; Fornoni, A. Implications of Sphingolipid Metabolites in Kidney Diseases. Int. J. Mol. Sci. 2022, 23, 4244. https://doi.org/10.3390/ijms23084244

AMA Style

Mallela Sk, Merscher S, Fornoni A. Implications of Sphingolipid Metabolites in Kidney Diseases. International Journal of Molecular Sciences. 2022; 23(8):4244. https://doi.org/10.3390/ijms23084244

Chicago/Turabian Style

Mallela, Shamroop k., Sandra Merscher, and Alessia Fornoni. 2022. "Implications of Sphingolipid Metabolites in Kidney Diseases" International Journal of Molecular Sciences 23, no. 8: 4244. https://doi.org/10.3390/ijms23084244

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop